



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Description

The Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Kit is an ELISA designed to analyze the ability of Bispecific Antibodies (BsAbs) to bridge CD19 (cluster of differentiation 19) and CD3 (cluster of differentiation 3) for screening and profiling applications. This assay kit can determine if an anti-CD19-anti-CD3 bispecific antibody binds to both targets simultaneously and bridges CD19 to CD3. The Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Assay Kit comes with enough recombinant human CD19 (amino acids 20-291), CD3-Containing Detection Reagent, and assay buffer for 100 enzyme reactions. This kit also includes Anti-CD19-Anti-CD3 Bispecific Antibody as a positive control.




Figure 1: Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Assay Kit principle.

A 96-well plate is coated with CD19 protein. After coating, an anti-CD19-anti-CD3 bispecific antibody is added in an optimized assay buffer. The plate is washed to remove unbound anti-CD19-anti-CD3 bispecific antibody. The plate is then incubated with CD3-Containing Detection Reagent. Finally, ELISA ECL substrate is added to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the bridging efficacy.

Background

Bispecific antibodies (BsAbs) are antibodies that have binding sites directed against different antigens or different epitopes of the same antigen. They are composed of heavy and light chains, and the appropriate chain matching is required for efficacy. To enhance the chance of chain matching and different applications, more than 30 different technologies have been developed, such as knob-into hole, ART-Ig, BiTE (bispecific cell engager) and others. They have gained attention for the treatment of cancer and other disorders due to their superior cytotoxicity effects and less development of resistance to their use. BsAbs can act as immune cell-cancer cell bridges, enhancing the killing potential of the immune cells. Current BsAbs have a CD3, CD16 or CD47 as one of the binding domains, and target CD19, PD-1, LAG-3, PSMA, mesothelin or other tumor antigens with the other. B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3C, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells, and is involved in the balance of humoral, antigen-induced and tolerance responses. Its presence in normal and neoplastic B cells has made it an attractive target in cancer therapy. Blinatumomab is a CD19/CD3 BiTE already approved by the FDA for use in patients with refractory or relapsed B-cell precursor ALL (acute lymphoblastic leukemia), and now being considered in CLL (chronic lymphocytic leukemia) treatment. The development of new BsAbs targeting CD19 and CD3 and formats will continue to bring benefits to patients suffering from CD19⁺ cancer types.

Applications

Study CD19:CD3 complex formation and assess the binding of BsAbs to their dual-antigen targets simultaneously for drug discovery and high throughput screening (HTS).

Note: Suitable for use with human serum, cell culture supernatants, and with purified proteins.

Supplied Materials

Catalog #	Name	Amount	Storage
	CD19, Avi-His-Tag*	10 µg	-80°C
101076	Anti-CD19-Anti-CD3 IgG format Bispecific Antibody*	10 µg	-80°C
82705	CD3- Containing Detection Reagent	6 µl	-80°C
82620	5x PP-02 Buffer	4 ml	-80°C
82765	Blocking Buffer 9	50 ml	+4°C
	ELISA ECL Substrate A (translucent bottle)	6 ml	Room Temp
79670	ELISA ECL Substrate B (brown bottle)	6 ml	Room Temp
79699	White 96-well microplate	1	Room Temp

**The concentration of the proteins is lot-specific and will be indicated on the tube.*

Materials Required but Not Supplied

- Test Samples (purified recombinant proteins, human serum, cell culture supernatant)
- 1x PBS (Phosphate Buffer Saline)
- PBST Buffer (1x PBS with 0.05% Tween-20)
- Microplate reader capable of reading luminescence
- Adjustable micropipettor and sterile tips
- Orbital shaker

Storage Conditions



This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed.

Safety



This product is for research purposes only and not for human or therapeutic use. This product should be considered hazardous and is harmful by inhalation, in contact with skin, eyes, clothing, and if swallowed. If contact occurs, wash thoroughly.

Contraindications

This kit is compatible with up to 1% DMSO.

Assay Protocol

- All samples and controls should be performed in duplicate.
- The assay should include “Blank”, “Positive Control”, and “Test Sample” conditions.
- We recommend maintaining the diluted proteins on ice during use.
- For detailed information on protein handling please refer to [Protein FAQs \(bpsbioscience.com\)](https://bpsbioscience.com).
- Variation in sample collection, processing and storage may cause differences in sample assay results.
- If using human serum or cell culture supernatant we recommend the use of LysA™ Protease Inhibitor Cocktail Kit (#82199) during sample preparation and analysis.
- We recommend using Anti-CD19-Anti-CD3 Bispecific Antibody (#101076) as internal control. If not running a dose response curve for the control bsAb, we recommend running the Anti-CD19-Anti-CD3 Bispecific Antibody at 0.1X, 1X and 10X the EC₅₀ value shown in the validation data below.
- For instructions on how to prepare reagent dilutions please refer to Serial Dilution Protocol (<https://bpsbioscience.com/serial-dilution-protocol>).

Step 1: Coat 96-well plate

Coat the plate one day prior to running your samples.

1. Thaw CD19 on ice. Briefly spin the tube containing the protein to recover its full content.
2. Dilute CD19 protein to 2 ng/μl with 1x PBS (50 μl/well).
3. Add 50 μl of diluted CD19 to every well.
4. Incubate at 4°C overnight.
5. Wash the plate three times using 200 μl of PBST Buffer per well.
6. Tap the plate onto a clean paper towel to remove the liquid.
7. Block the wells by adding 200 μl of Blocking Buffer 9 to every well.
8. Incubate at Room Temperature (RT) for at least 90 minutes.
9. Wash the plate three times using 200 μl of PBST Buffer per well.
10. Tap the plate onto a clean paper towel to remove the liquid.

Step 2: Bispecific Bridging

1. Prepare 1x Assay Buffer by diluting 5x PP-02 Assay Buffer 5-fold with distilled water.
2. Prepare the diluted Anti-CD19-Anti-CD3 Bispecific Antibody control (Control BsAb) (50 μl/well).
 - 2.1 Thaw Anti-CD19-Anti-CD3 Bispecific Antibody on ice. Briefly spin the tube to recover the full content of the tube.

Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Assay Kit

- 2.2 For a dose response curve prepare a serial dilution starting at 40 ng/ μ l of the Anti-CD19-Anti-CD3 Bispecific Antibody with 1x Assay Buffer (50 μ l/well).
3. Add 50 μ l of diluted Anti-CD19-Anti-CD3 Bispecific Antibody to the "Positive Control" wells.
 4. Prepare serial dilutions of the biologic of interest (test sample) with 1x Assay Buffer at the desired final concentrations 50 μ l/well).
 5. Add 50 μ l of each test sample to the wells labeled "Test Sample".
 6. Add 50 μ l of 1x Assay Buffer to "Blank" wells.

	Blank	Positive Control	Test Sample
1x Assay Buffer	50 μ l	-	-
Test Sample	-	-	50 μ l
Control BsAb	-	50 μ l	-
Total	50 μl	50 μl	50 μl

7. Incubate the plate at RT with slow agitation for 1 hour.
8. Wash the plate three times with 200 μ l of PBST Buffer per well and tap the plate onto a clean paper towel.
Note: Additional blocking may improve S/N ratio. If necessary, block the wells by adding 200 μ l of Blocking Buffer 9 to every well for 10 min.
9. Thaw CD3-Containing Detection Reagent on ice. Briefly spin the tube containing the protein to recover its full content.
10. Dilute the CD3-Containing Detection Reagent 1000-fold with Blocking Buffer 9 (50 μ l/well).
11. Add 50 μ l of diluted CD3-Containing Detection Reagent to all wells.
12. Incubate the plate at RT with slow agitation for 1 hour.
13. Wash the plate three times with 200 μ l of PBST Buffer per well and tap the plate onto a clean paper towel.

Step 3: Detection

1. Just before use, mix 1 volume of ELISA ECL Substrate A and 1 volume of ELISA ECL Substrate B (100 μ l of mix/well).
2. Add 100 μ l of mix to every well.

3. Immediately read the plate in a luminometer or microtiter-plate reader capable of reading chemiluminescence.
4. The “Blank” value should be subtracted from all other values.

Reading Chemiluminescence

Chemiluminescence is the emission of light (luminescence) which results from a chemical reaction. The detection of chemiluminescence requires no wavelength selection because the method used is emission photometry and is not emission spectrophotometry.

To properly read chemiluminescence, make sure the plate reader is set for LUMINESCENCE mode. Typical integration time is 1 second, delay after plate movement is 100 msec. Do not use a filter when measuring light emission. Typical settings for the Synergy 2 BioTek plate reader are: use the “hole” position on the filter wheel; Optics position: Top; Read type: endpoint. Sensitivity may be adjusted based on the luminescence of a control assay without enzyme (typically we set this value as 100).

Example Results




Figure 1. Simultaneous binding abilities of two different Anti-CD19-Anti-CD3 Bispecific Antibodies to their dual-antigen targets.

The bridging abilities of two BsAb targeting CD19 and CD3 (#101076 and #100441) were validated using Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Assay Kit. Luminescence was measured using a Bio-Tek microplate reader. Results are presented as a percentage of bridging in which the maximal binding is set to 100%.

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

References

- Robinson H., et al., 2018 *Blood* 132 (5): 521-532.
 Ma J., et al., 2021 *Front Immunol.* 12:626616.

Troubleshooting Guide

Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com

Related Products

Products	Catalog #	Size
CD19 Lentivirus	78657	500 µl x 2
Anti-CD19 IgG Antibody	100981	50 µg/ 100 µg
Anti-CD19 IgG Antibody, Biotin-Labeled	101093	50 µg/ 100 µg
Firefly Luciferase Raji Cell Line	78622	2 vials
Firefly Luciferase NALM6 Cell Line	78494	2 vials
CD19 CHO Recombinant Cell Line (Low, Medium and High Expression)	79561	2 vials

Version 110824